List view / Grid view

James Foster

 

news

Nimbus Therapeutics enters into strategic partnership with Charles River Laboratories to advance new therapeutic programs

Nimbus Therapeutics and Charles River Laboratories International, Inc. (NYSE: CRL)…

5 April 2017 | By

Nimbus Therapeutics and Charles River Laboratories International, Inc. (NYSE: CRL) launched a multi-year strategic partnership to advance new programs spanning the disease areas of immunology, metabolic disorders and oncology from the discovery phase through to Investigational New Drug (IND) submission.